AndHealth Dermatology Welcomes Dr. Drew Kurtzman to Its Practice in Kentucky and Ohio




AndHealth Dermatology Welcomes Dr. Drew Kurtzman to Its Practice in Kentucky and Ohio

COLUMBUS, Ohio–(BUSINESS WIRE)–AndHealth Dermatology has welcomed Dr. Drew Kurtzman to its practice starting in May 2025. Dr. Kurtzman is a renowned board-certified dermatologist from Kentucky who will now see patients in Kentucky and Ohio as a part of AndHealth Dermatology. Appointments can be scheduled by calling 614-398-0582, by emailing appointments@andhealth.com, or by visiting DrDrewKurtzmanDermatologist.com.

Dr. Kurtzman brings a deep commitment to providing compassionate, expert care for patients with complex skin conditions. He has advanced training in both dermatology and rheumatology, allowing him to offer highly specialized care for patients with autoimmune and inflammatory skin conditions. Dr. Kurtzman’s approach blends cutting-edge medical knowledge with a genuine focus on patient well-being, ensuring each individual receives personalized treatment tailored to their unique needs.

With over a decade of clinical experience, Dr. Kurtzman has served in both academic and private practice settings. Patients value his thoroughness, clear communication, and dedication to improving quality of life through effective dermatologic care. Whether managing chronic conditions or evaluating new concerns, Dr. Kurtzman strives to make every patient feel heard, informed, and supported throughout their journey to healthier skin.

By practicing at AndHealth, Dr. Kurtzman will now offer access to an integrated care model that provides everything patients need to be well. AndHealth combines convenient, affordable, and high-quality dermatology and rheumatology care with pharmacy services and comprehensive support for root causes, such as medically tailored meal delivery, sleep, movement, remote monitoring, and continuous access to providers and health coaching.

AndHealth upholds ambitious benchmarks for patients, including a 94 Net Promoter Score (NPS) for patient satisfaction. Patients will also no longer face long drives or delays, as patients can be seen virtually or in person and nine out of 10 patients have their first visit in under just two weeks.

Dr. Kurtzman is looking forward to continuing patient care at AndHealth and said, “AndHealth Dermatology epitomizes the real definition of healthcare: supporting a person’s ability to heal and be whole. AndHealth Dermatology does this by leveraging technology, behavioral change and cutting-edge medicines to empower our patients to own their health outcomes. These resources and core values are why I couldn’t imagine practicing medicine anywhere other than AndHealth Dermatology.”

About AndHealth Dermatology

AndHealth Dermatology provides comprehensive dermatology care alongside unique world-class services to meet the unique needs of patients with chronic autoimmune conditions, by directly integrating pharmacy support for complex specialty medications and personalized care plans that include continuous care delivery including health coaching, medically tailored meals, sleep and movement support, remote monitoring, and everything else patients need to be well.

Headquartered in Columbus, Ohio, AndHealth Dermatology treats patients in Ohio, Kentucky, Indiana, Boston, and soon Illinois (coming in mid-2025).

To learn more or schedule, visit DrDrewKurtzmanDermatologist.com.

Contacts

Julia Phillips

SVP, Marketing

AndHealth

press@andhealth.com

MeMed BV Surpasses 100,000 Patient Tests, Underscoring Adoption of Rapid Host-Response Diagnostics




MeMed BV Surpasses 100,000 Patient Tests, Underscoring Adoption of Rapid Host-Response Diagnostics

— Milestone Achieved Through Growing Clinical Evidence Demonstrating Real-World Impact on Infection Management —

— MeMed and Physicians Premier Celebrated Milestone Event in Corpus Christi, Texas —

ANDOVER, Mass. & HAIFA, Israel–(BUSINESS WIRE)–#AMR–MeMed, a global leader in host-response diagnostics, today announced a major milestone: more than 100,000 patients have now been tested with MeMed BV^®, the company’s flagship diagnostic that accurately distinguishes between bacterial and viral infections in just 15 minutes, based on the body’s immune response. This milestone highlights MeMed’s commitment to advancing precision medicine, empowering responsible antibiotic use by care providers, and transforming infection management across diverse care settings.

Advancing Antibiotic Stewardship and Clinical Decision-Making

The growing adoption of MeMed BV in emergency medicine, urgent care, and hospital settings indicates the industry’s move toward host-response and precision diagnostics. From hospital systems to decentralized care providers, MeMed BV has been integrated into real-world clinical workflows by clinicians committed to improving patient outcomes.

Among these trailblazing partners is Physicians Premier, an innovative network of freestanding emergency rooms that has embraced MeMed BV as part of its commitment to advanced, patient-centered care. The 100,000th patient test was performed at Physicians Premier’s Parkdale clinic in Corpus Christi, Texas, a symbolic moment that was marked with a joint celebration between MeMed and Physicians Premier leadership earlier today.

“At Physicians Premier, we are committed to delivering cutting edge, personalized care that prioritizes both patient well-being and best practices,” said Teri Cardenas, CEO of Physicians Premier. “MeMed BV has empowered our clinicians to make more informed decisions, reducing unnecessary antibiotic prescriptions while improving patient outcomes. We are proud to stand with MeMed at the forefront of diagnostic innovation.”

Scaling Global Impact through Strategic Partnerships

The 100,000-test milestone represents broader industry shifts toward rapid host-response diagnostics and underscores MeMed’s global growth strategy. The company remains focused on scaling through partnerships with decentralized and hospital-based providers, integrating high-throughput analyzers to serve acute care settings, and collaborating on distribution agreements across the U.S., Europe, and emerging markets.

“Crossing the 100,000-patient mark is more than a milestone—it’s a meaningful indicator of the clinical value we’re delivering,” said Eran Eden, Ph.D., Co-Founder and CEO of MeMed. “It reflects the trust of a growing network of forward-thinking healthcare partners like Physicians Premier, as we jointly transform the landscape of infectious disease management. With only a fraction of the potential market reached—and backed by strong clinical evidence and strategic partnerships—we anticipate accelerating momentum, bringing critical answers to clinicians and patients when they matter most.”

MeMed continues to engage healthcare providers and industry leaders to advance adoption of rapid, reliable diagnostics that improve patient care.

About MeMed

At MeMed, our mission is to translate the immune system’s complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society.

MeMed BV^® is the first FDA-cleared host-immune response test for accurately distinguishing between bacterial and viral infections in 15 minutes.

MeMed Severity™ has received FDA Breakthrough Device Designation as a host-response test designed to aid early risk assessment in ED patients with suspected infection or sepsis. It predicts severe outcomes within 72 hours and mortality within 14 days. MeMed Severity is not yet cleared for sale in any territory.

Follow and connect with MeMed via LinkedIn, Twitter/X, and Facebook.

Contacts

MeMed Contact:
Tal Avziz

Vice President, Global Marketing

pr@me-med.com

Media Relations Contact:
Charya Wickremasinghe, Ph.D.

Brandwidth Solutions LLC

cwickremasinghe@brandwidthsolutions.com

Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio




Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio

SWEDESBORO, N.J.–(BUSINESS WIRE)–#AnimalHealth–Wedgewood Pharmacy today announced the availability of a GS-441524 formula, a compounded oral antiviral formulation now part of its feline infectious peritonitis (FIP) treatment capabilities. With this addition, veterinarians can now prescribe both GS-441524 and Molnupiravir for their patients, two of the most requested compounded antivirals for FIP, through a single trusted source backed by pharmacist support and FDA-registered ingredient sourcing.

GS-441524 can be compounded as a 50mg/ml flavored oral oil suspension in multiple sizes, to improve compliance and ease of administration. The addition complements Wedgewood’s Molnupiravir formulations, giving veterinarians access to two antivirals with distinct mechanisms of action.

“FIP is one of the toughest diagnoses we face, not just clinically, but emotionally too,” said Dr. Rae Hutchins, Chief Veterinary Officer at Wedgewood. “For a long time, vets had to deal with inconsistent access and quality when it came to GS-441524. Now, by offering both GS-441524 and Molnupiravir from one trusted, pharmacist-supported source, we’re making it easier for veterinarians to focus on what matters most, giving their patients the best possible chance.”

“Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment to best suit the needs of their patients and clients,” said Nicole Jacque, co-founder of FIP Global Cats. “Having pharmacists who understand the urgency and complexity of these cases partnering with veterinarians is key to ensuring the best treatment outcomes for cats with FIP.”

Until recently, many veterinarians relied on fragmented or unregulated sources for GS-441524, making it difficult to ensure consistency and continuity of care. The introduction of this option through Wedgewood reflects a direct response to those challenges, providing prescribers with a trusted, quality-assured formulation from a pharmacy they can count on.

The launch of GS-441524 builds on Wedgewood’s long-standing role in supporting veterinarians with customized treatment solutions for complex cases. As part of its commitment to responsible compounding, the pharmacy emphasizes that its GS-441524 formulation is not approved by the FDA, has not been studied in clinical trials, and Wedgewood makes no claims of efficacy or safety. Independent third-party studies related to GS-441524 are available for veterinary reference through Wedgewood’s FIP Resource Center.

To learn more about GS-441524 and access educational resources, visit www.Wedgewood.com/FIP.

About Wedgewood

Wedgewood is the nation’s largest and most trusted provider of compounded veterinary medications. Its next-generation home delivery platform, Blue Rabbit, streamlines patient care and marks a significant evolution in online pharmacy services. Together, Blue Rabbit and Wedgewood serve more than 70,000 veterinary professionals and more than one million animals annually. For more information visit www.Wedgewood.com.

About FIP Global Cats

FIP Global CATS® (Community, Advocacy, Treatment, Support) is a leading organization in the fight against feline infectious peritonitis (FIP). Uniting veterinarians, researchers, and pet owners, it provides crucial support to those facing an FIP diagnosis. The organization is committed to empowering pet parents, advocating for safe, effective and affordable legal treatments, and advancing FIP research. For more information, please visit https://www.fipglobalcats.com/.

Contacts

Jennifer Ravalli

jennifer.ravalli@wedgewood.com

Competitive Landscape in Healthcare Super Centers: Analysis of Key Players Leading Market Transformation, including CVS Health, Walmart Health, Emitac Healthcare Solutions and Mediclinic Middle East – ResearchAndMarkets.com




Competitive Landscape in Healthcare Super Centers: Analysis of Key Players Leading Market Transformation, including CVS Health, Walmart Health, Emitac Healthcare Solutions and Mediclinic Middle East – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Healthcare Super Centers Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F” has been added to ResearchAndMarkets.com’s offering.

The Healthcare Super Centers Market was valued at USD 2.75 Billion in 2024, and is expected to reach USD 4.81 Billion by 2030, rising at a CAGR of 9.74%.

Healthcare Super Centers – also known as medical malls – are comprehensive health hubs designed to provide a wide array of medical services under one roof. These advanced facilities centralize access to general practitioners, specialists, diagnostic labs, pharmacies, and other health-related services, enabling patients to receive coordinated care in a single visit. By integrating services into one location, these centers streamline the patient journey, reduce wait times, and improve overall care efficiency.

The use of shared electronic health records (EHRs) ensures seamless information exchange among providers, enhancing treatment accuracy and patient outcomes. As patient expectations evolve toward convenience, transparency, and holistic care, Healthcare Super Centers are emerging as a pivotal model in transforming how medical services are delivered globally.

Key Market Drivers: Rising Demand of Comprehensive Care

The increasing preference for all-in-one healthcare solutions is driving the demand for Healthcare Super Centers. These facilities offer patients the convenience of accessing various services – including primary care, diagnostics, pharmacy, imaging, and specialty consultations – in a single location. This centralized approach eliminates the need for multiple appointments across different providers, saving time and simplifying the healthcare process.

By integrating services, super centers expedite diagnoses and treatment, particularly for urgent or chronic conditions, while fostering better communication among healthcare teams. They also promote preventive health through wellness programs, screenings, and lifestyle counseling. As the focus shifts toward patient-centric models and proactive health management, the appeal of super centers continues to grow. The combination of efficiency, comprehensiveness, and convenience positions them as a key solution for modern healthcare delivery.

Key Market Challenges: Regulatory and Licensing Hurdles

Launching and operating a Healthcare Super Center involves navigating a complex landscape of regulatory and licensure requirements, which differ significantly across regions. These centers often need multiple licenses covering diverse services, such as diagnostics, emergency care, and specialty consultations. The credentialing of healthcare providers within the facility adds further administrative complexity, requiring verification of qualifications, experience, and certifications.

In addition to meeting healthcare-specific laws, operators must comply with data privacy regulations, building codes, and safety standards. This multi-layered regulatory framework demands significant time, resources, and legal oversight. For new entrants, particularly those expanding into new jurisdictions, these compliance challenges can delay project timelines and inflate startup costs. Ensuring legal and operational alignment with local healthcare authorities is critical to maintaining high standards of care and patient safety.

Key Market Trends: Telehealth Integration

A prominent trend in the Healthcare Super Centers Market is the integration of telehealth services, enabling flexible and accessible care delivery. Telehealth bridges geographic gaps and enhances patient convenience, especially for those in remote or underserved areas. Through virtual consultations, patients can address minor illnesses, refill prescriptions, or manage chronic conditions without traveling to a facility. This hybrid care model – combining in-person and remote interactions – ensures consistent follow-up and care continuity.

Remote patient monitoring solutions also allow providers to track health metrics and intervene when necessary, improving outcomes for those recovering post-surgery or living with chronic diseases. As digital health tools gain traction, telehealth services are becoming a core offering in super centers, aligning with modern expectations for accessible, tech-enabled healthcare.

Key Market Players:

• CVS Health Corporation
• Walmart Health Centers
• Taskar Group
• Al Falah Healthcare Center
• Emitac Healthcare Solutions
• Mediclinic Middle East
• Jackson Medical Mall Foundation

Key Attributes:

Report Scope:

In this report, the Global Healthcare Super Centers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Healthcare Super Centers Market, By Services:

• Primary Medical Services
• Dental Care
• Diagnostic Services
• Behavioural Health Services
• Pharmacy Services
• Telemedicine
• Others

Healthcare Super Centers Market, By Product:

• Medicines
• Dietary-Nutrition & Supplements
• Health & Wellness
• Nursing Supplies
• Health Gadgets
• Rehabilitation Products & Aids
• Baby Products
• Others

Healthcare Super Centers Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

For more information about this report visit https://www.researchandmarkets.com/r/xwtom6

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Oncolytic Virus Immunotherapy Strategic Research Business Report 2025-2030: Surge in Clinical Trials Combining Oncolytic Viruses With Checkpoint Inhibitors Expands Therapeutic Horizons – ResearchAndMarkets.com




Oncolytic Virus Immunotherapy Strategic Research Business Report 2025-2030: Surge in Clinical Trials Combining Oncolytic Viruses With Checkpoint Inhibitors Expands Therapeutic Horizons – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Oncolytic Virus Immunotherapy – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering.

The global market for Oncolytic Virus Immunotherapy was valued at US$156.8 Million in 2024 and is projected to reach US$429.1 Million by 2030, growing at a CAGR of 18.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Oncolytic Virus Immunotherapy market.

Oncolytic virus immunotherapy is gaining renewed momentum in oncology as a dual-action therapeutic strategy that combines direct tumor lysis with immune system priming. These genetically engineered or naturally occurring viruses selectively infect and replicate in tumor cells, causing their destruction while releasing tumor-associated antigens that stimulate anti-cancer immune responses. Unlike traditional chemotherapy or radiation, oncolytic viruses act locally at the tumor site and systemically through immune activation, positioning them as versatile agents in both solid and hematologic malignancies.

What Is Powering Long-Term Growth and Scientific Innovation in the Oncolytic Virus Immunotherapy Market?

The growth in the oncolytic virus immunotherapy market is powered by a paradigm shift toward immune-driven cancer control, rising incidence of refractory tumors, and growing regulatory openness to gene-modified biologicals. Oncolytic viruses offer a platform approach with customizable payloads and delivery options, making them highly adaptable to evolving immuno-oncology landscapes. Their ability to initiate cold-to-hot tumor conversion addresses one of the biggest challenges in cancer immunotherapy today.

Pharmaceutical companies are accelerating R&D through collaborations with academic virologists, biotech firms, and clinical oncology networks. AI-driven viral vector design, CRISPR-enabled transgene integration, and intratumoral microdosing techniques are improving specificity and safety profiles. Investment in scalable manufacturing, lyophilized formulations, and cold-chain logistics is supporting broader market readiness. As personalized cancer vaccines and immune cell therapies gain traction, oncolytic viruses are poised to serve as immune amplifiers that bridge innate and adaptive response layers. The future of cancer immunotherapy will be increasingly shaped by these programmable, self-amplifying, and immune-sensitizing viral agents.

How Are Genetic Engineering and Combination Protocols Expanding the Potential of Oncolytic Virotherapy?

Recent breakthroughs in synthetic biology and vector engineering are significantly enhancing the safety, selectivity, and immune-stimulatory capabilities of oncolytic viruses. New viral constructs – based on herpes simplex virus (HSV), adenovirus, vaccinia virus, and reovirus – are being armed with immune-boosting transgenes such as GM-CSF, interleukins, or checkpoint blockade peptides. These modifications allow the virus to not only destroy tumor cells but also convert the tumor microenvironment (TME) into an immunologically active site.

Combination therapies are a major focus, with oncolytic viruses increasingly paired with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1), CAR-T therapies, or radiotherapy to overcome resistance mechanisms and enhance systemic anti-tumor responses. Intratumoral delivery methods, dose escalation protocols, and multi-site administration strategies are improving virus biodistribution and reducing off-target effects. Liquid biopsy and imaging biomarkers are being developed to monitor viral persistence, immune infiltration, and treatment response in real time. These advancements are transitioning oncolytic virotherapy from a niche modality into an integral component of multi-modal cancer treatment frameworks.

Which Tumor Types and Geographies Are Shaping the Clinical and Commercial Landscape for Oncolytic Viruses?

Solid tumors with immunosuppressive microenvironments – such as melanoma, glioblastoma, pancreatic cancer, and hepatocellular carcinoma – are prime candidates for oncolytic virotherapy. These cancers typically respond poorly to conventional therapies and often lack T-cell infiltration, which oncolytic viruses can help overcome. Hematologic malignancies like lymphoma and multiple myeloma are also being targeted through engineered viruses capable of engaging both innate and adaptive immunity.

North America leads clinical development, with the U.S. hosting the majority of early-phase and pivotal trials. The presence of major virotherapy developers, robust funding ecosystems, and an innovation-friendly regulatory environment accelerates translational progress. Europe follows with strong academic-industry partnerships and regulatory support through the EMA’s Advanced Therapy Medicinal Product (ATMP) designation. Asia-Pacific is emerging as a competitive landscape, particularly in China, where biotech firms are investing heavily in oncolytic platforms and regulatory reforms are enabling faster trial initiation. Global oncology centers are increasingly integrating oncolytic viruses into compassionate use programs and combination trial protocols.

Report Scope

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Amgen Inc., CG Oncology, Creative Biolabs, Daiichi Sankyo Co., Ltd., Genelux Corporation and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Herpes Simplex Virus segment, which is expected to reach US$189.7 Million by 2030 with a CAGR of a 18.6%. The Vaccinia Virus segment is also set to grow at 15.3% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $42.7 Million in 2024, and China, forecasted to grow at an impressive 24.8% CAGR to reach $99.7 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Segments

• Type (Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus, Other Types)
• Administration Route (Intratumoral Route, Intravenous Route)
• Application (Melanoma Application, Non-small Cell Lung Cancer Application, Pancreatic Cancer Application, Breast Cancer Application, Other Applications)

Tariff Impact Analysis: Key Insights for 2025

What’s Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry

Key Attributes:

Key Topics Covered:

MARKET OVERVIEW

• Influencer Market Insights
• World Market Trajectories
• Impact of COVID-19 and a Looming Global Recession
• Oncolytic Virus Immunotherapy – Global Key Competitors Percentage Market Share in 2025 (E)
• Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)

MARKET TRENDS & DRIVERS

• Rising Focus on Precision Oncology Spurs Development of Oncolytic Virus Platforms With Tumor Selectivity
• Expansion of Immunotherapy Research Pipelines Strengthens Business Case for Oncolytic Virus Modalities
• Increased Approval of Cancer Immunotherapies Throws the Spotlight on Next-Generation Viral Vectors
• Breakthrough Designation Status and Fast Track Approvals Accelerate Regulatory Momentum
• Advancements in Genetic Engineering of Viruses Drive Enhanced Tumor Targeting and Immune Activation
• Surge in Clinical Trials Combining Oncolytic Viruses With Checkpoint Inhibitors Expands Therapeutic Horizons
• Increased Use of Oncolytic Viruses as Neoadjuvant Therapies Supports Multimodal Cancer Management
• Growing Investment From Biopharma and Venture Capital Enhances Innovation and Clinical Translation
• Development of Tumor-Specific Viral Payloads Strengthens Oncolytic Virus Selectivity and Safety Profiles
• Adoption of Intratumoral and Systemic Delivery Routes Expands Accessibility to Diverse Tumor Types
• Improved Understanding of Tumor Microenvironment Enhances Viral Mechanism Optimization
• Collaborative Efforts Between Academia and Industry Propel Translational Research in Viral Oncology
• Expansion of Cold Chain Logistics Infrastructure Supports Global Supply of Virus-Based Therapies
• Public and Philanthropic Funding for Rare Cancer Treatment Drives Orphan Application Development
• Manufacturing Scale-Up of Viral Vectors Remains a Bottleneck for Commercialization Readiness
• Development of Immune Response Biomarkers Facilitates Patient Selection and Treatment Monitoring
• Increased Advocacy for Personalized Cancer Immunotherapy Supports Patient Enrollment in Viral Trials
• Challenges in Viral Shedding and Immunogenicity Highlight Need for Improved Safety Profiling
• Rising Global Cancer Incidence and Limited Success in Refractory Cancers Propel Need for Disruptive Modalities
• Regulatory Alignment on Gene and Virus Therapies Enhances Global Clinical Trial Harmonization

FOCUS ON SELECT PLAYERS: Some of the 41 companies featured in this report

• Amgen Inc.
• CG Oncology
• Creative Biolabs
• Daiichi Sankyo Co., Ltd.
• Genelux Corporation
• ImmVirX
• Imugene Limited
• Lokon Pharma AB
• Merck & Co., Inc.
• Oncolys BioPharma Inc.
• Oncolytics Biotech Inc.
• Oncorus Inc.
• Replimune Group Inc.
• SillaJen, Inc.
• Sorrento Therapeutics, Inc.
• Syneos Health, Inc.
• TILT Biotherapeutics Ltd.
• Transgene S.A.
• Viralytics Ltd.
• ViraTherapeutics GmbH

For more information about this report visit https://www.researchandmarkets.com/r/uq4wts

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Immersive AI Platform for Pathologists Set to Launch at CAP25 in Orlando




Immersive AI Platform for Pathologists Set to Launch at CAP25 in Orlando

NORTHFIELD, Ill.–(BUSINESS WIRE)–A new virtual artificial intelligence (AI) platform for pathologists will debut at CAP25, September 13-16 in Orlando, to give pathologists experience with the technology.

The College of American Pathologists’ (CAP) platform, powered by PathPresenter’s technology, will provide CAP members a safe, simulated space to explore cutting-edge AI tools used in pathology. From image analysis to diagnostic support, pathologists can interact with models in realistic patient scenarios without impacting care.

“It’s no risk, no pressure. Just discovery,” said CAP President Donald Karcher, MD, FCAP. “This initiative is about giving pathologists a trusted environment to evaluate new tools and stay in control of how technology fits into pathology practice.”

Designed as both an educational tool and a discovery hub, the platform is set to become a go-to destination for pathologists exploring AI in real-world contexts when launched at CAP25.

“We wanted to give pathologists a space to explore how AI models can be used in real-world practice,” said M. E. (Doc) de Baca, MD, FCAP, CAP Council on Informatics and Pathology Innovation Chair. “This platform not only highlights the AI tools currently available and also offers a glimpse of what’s possible as we continue to investigate how AI can support and enhance the practice of pathology.”

The platform will feature a slate of AI tools for the pathology community to test drive, with participation from vendors across the industry. Pathologists will be able to engage with real models, not just screenshots or quick demos. It’s designed to meet the growing demand for meaningful, hands-on exploration of AI tools in a setting that supports learning and confidence.

“Pathologists are looking for more than marketing jargon,” said Rajendra Singh, MD, FCAP, co-founder of PathPresenter. “They want evidence. They want to see first-hand how these tools perform, what problems they solve, and how they fit into real pathology workflows. This platform brings together the best of both worlds: innovative AI models and expert users who know how to critically evaluate them.”

The initiative is guided by CAP leaders at the forefront of informatics, AI, and digital innovation, bringing deep expertise and a clear focus on what pathologists need most from emerging technologies.

About the College of American Pathologists

As the world’s largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, visit the CAP Newsroom, CAP.org and yourpathologist.org to watch pathologists at work and see the stories of the patients who trust them with their care.

About PathPresenter

PathPresenter is an enterprise image management and workflow platform for digital pathology. We are on a mission to democratize access to the world’s pathology knowledge by connecting pathologists to the vast expertise of their colleagues globally and providing a practical platform to access and use best-in-class AI models. Founded by dermatopathologist and digital pathology pioneer Dr. Rajendra Singh, PathPresenter’s secure, scalable, vendor-agnostic enterprise pathology workflow software has been adopted by tier one medical institutions for clinical care, education, and research, and the company has built a thriving community of tens of thousands of users around the world to easily view and share digital pathology images and knowledge. Learn more at www.pathpresenter.com.

Contacts

Angela Panateri

apanate@cap.org

MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial




MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial

CHICAGO–(BUSINESS WIRE)–MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced a new partial response (PR) was identified in a patient after 20 months of treatment in its Phase 2 THIO-101 clinical trial evaluating ateganosine (THIO), sequenced with Regeneron’s immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who are resistant to immune therapy and chemotherapy. A partial response is defined as a decrease in tumor size of at least 30%.

“The patient remained on treatment and we observed stable disease for more than twenty months before the partial response was identified, highlighting the efficacy, safety and low toxicity of the treatment. Extended-term responses like this are not often seen in heavily pretreated patients in hard-to-treat diseases such as NSCLC, where the prognosis for the advanced-stage of the disease is typically poor,” said MAIA Chairman and CEO Vlad Vitoc, M.D. “We confirmed this response with a second scan, and we are highly confident that ateganosine could become an outstanding therapeutic alternative for third-line NSCLC patients.”

THIO-101 third line (3L) data cutoff from May 15, 2025, showed median overall survival (OS) of 17.8 months for the 22 NSCLC patients who received at least one dose of ateganosine in parts A and B of the trial. At the data cutoff, the patient with the longest survival in the trial had completed 32 cycles of therapy and had 24.3 months survival. Studies of standard-of-care (SOC) chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months.¹

MAIA has announced the trial design for an expansion of its THIO-101 pivotal Phase 2 trial in NSCLC to assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous CPI treatment and chemotherapy.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

¹ Girard N, et al. J Thorac Onc 2009;12:1544-1549.

Contacts

Investor Relations Contact
+1 (872) 270-3518

ir@maiabiotech.com

Publication in Vaccines Highlights Important Benefits of PharmaJet® Tropis® Intradermal Vaccination over Intramuscular Standard of Care




Publication in Vaccines Highlights Important Benefits of PharmaJet® Tropis® Intradermal Vaccination over Intramuscular Standard of Care

• Substantial Improvements in Coverage of IPV2. Vaccine coverage of the second dose of inactivated polio vaccine (IPV2) administered with Tropis ID increased by 11.2% compared to the standard of care (SoC, full dose delivered by needle and syringe intramuscular delivery). On a relative basis, the odds of receiving 2 doses of IPV are doubled when using Tropis ID.
• Preferred by Vast Majority of Healthcare Workers. Needle-free Tropis ID was the preferred method of vaccination for routine immunization (RI) as reported by 97% of healthcare workers surveyed, who cited that, compared to the SoC, Tropis ID was (i) easier to use (95%), and (ii) children experienced less discomfort (94%). 
• Significant Cost Reductions. Incremental savings with needle-free could range from US$0.07 to US$1.00 per dose, with up to 47% total immunization cost savings compared to the SoC in a full-scale scenario. This equates to a potential savings of ~US$50 million over a 5-year period using Tropis ID for the Nigeria immunization program.

GOLDEN, Colo.–(BUSINESS WIRE)–PharmaJet^®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that Vaccines has published the results of an implementation research study entitled Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria’s routine immunization program: An implementation hybrid trial.¹ The study, funded by a multi-year, US$1.5 million grant from the USAID Development Innovation Ventures Program, in collaboration with the Nigeria National Primary Health Care Development Agency (NPHCDA), Jhpiego, PATH, Sydani Group and Johns Hopkins Bloomberg School of Public Health, aimed to comparatively evaluate the vaccine coverage, cost, feasibility and acceptability of using Tropis ID for fIPV delivery compared to the SoC in a routine immunization program. A household survey was completed in Kano and Oyo States following a six-month implementation with children aged 3 to 12 months.

This study is the first to measure coverage benefits of Tropis ID in RI settings, adding to the evidence of the value of needle-free intradermal delivery in the global pursuit of polio eradication. While Nigeria improved full regimen coverage from 33% in 2016 to 57% in 2022,² it is actively pursuing new approaches that may bring further improvements to coverage and reduce costs as the country prepares for transition from Gavi support,³ while navigating funding reductions in global health programs. Tropis ID, a WHO pre-qualified needle-free delivery system, is an easy-to-use, precise, intradermal delivery method that has already been successfully used in campaign and house-to-house settings in high-risk polio environments, with over 12 million injections administered to date.⁴

The Vaccines publication highlighted that when compared to the SoC, Tropis ID demonstrated:

• Increased coverage: IPV2 coverage was 11.2% higher. On a relative basis, this means the odds of receiving 2 doses of IPV are doubled when Tropis ID is used.
• Cost savings: Up to 47% total immunization costs savings can be realized when using Tropis ID for IPV delivery,⁴ which equates to a potential savings for the Nigeria immunization program of ~US$50 million over a 5-year period.
• Acceptability: 97% of healthcare workers preferred Tropis ID for routine immunization, noting it is easy to operate, associated with less perceived discomfort by children during administration, and elicited a positive caregiver response.

“This study demonstrates that Tropis ID can improve the patient and caregiver experience over the standard of care for routine immunizations, resulting in increased vaccine compliance, which is an important element in eradicating polio,” said Paul LaBarre, Vice President Global Business Development, PharmaJet. “With the added benefits of intradermal dose sparing and the associated cost savings, Tropis ID is an ideal immunization tool. We look forward to collaborating with other African partners to assess the benefits needle-free ID delivery can provide for their immunization programs.”

Refer to Instructions for Use to ensure safe injections and to review risks.

¹ Mohan, D et al, Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria’s routine immunization program: An implementation hybrid trial , Vaccines,16 May 2025, 13(5), p.533

² 2023: A Critical Year for polio eradication efforts in northern Nigeria. Global Polio Eradication Initiative. 2023. (accessed on 21 March 2025)

³ Presentation of Evidence by the Polio Disease Working Group. Presented at the meeting of the Nigerian Immunization Technical Advisory Group, Abuja, Nigeria, 24 July 2018.

⁴ Data on file

About PharmaJet

The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. Tropis^® ID has CE Mark and WHO PQS certification for intradermal injections and is commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit https://www.pharmajet.com or contact PharmaJet here. Follow us on LinkedIn.

About The Global Polio Eradication Strategy (GPEI)

In 1988, the Global Polio Eradication Initiative (GPEI) was launched after a resolution passed by the World Health Assembly, with over 350,000 children recorded as having paralytic polio across 125 countries. The GPEI’s goals are to detect and stop the spread of poliovirus and strengthen immunization programs globally. Post-eradication strategies, such as sustaining high vaccination rates and strengthening surveillance efforts, are important in the goal of eradicating polio. The GPEI Polio Eradication Strategy 2022–2026 set 2023 as a target year to interrupt all remaining type 1 wild poliovirus (WPV1) transmission (Goal One) and type 2 circulating vaccine-derived poliovirus (cVDPV) transmission (Goal Two), with the aim of reaching eradication by 2026.

Contacts

Nancy Lillie

Nancy.Lillie@PharmaJet.com
1-888-900-4321 Option 3

Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia




Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia

Exclusive-Licensing Partner Santen Will Commercialize SYD-101 Under the Brand Name Ryjunea^® in the European Union

DEL MAR, Calif.–(BUSINESS WIRE)–Sydnexis, Inc., (www.sydnexis.com) a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company’s proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia. As the first and only approved pharmaceutical treatment option to treat myopia progression in EU countries, this approval marks a significant advancement in pediatric eye care. The approval is backed by data from the STAR study, Sydnexis’ pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow the progression of pediatric myopia and the risk of associated co-morbidities in children 3 to 14 years old at treatment initiation.

“This marks a significant milestone for Sydnexis and, most importantly, for pediatric patients with progressive myopia, their families, and physicians as the first and only approved pharmaceutical treatment option in Europe,” said Perry Sternberg, Chief Executive Officer of Sydnexis. “This approval is an endorsement of the potential benefit SYD-101 can provide to millions of patients globally and reinforces the critical importance of early intervention.”

The marketing approval from the EC follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP). Santen, a Japan-based company specialized in eye health, offering innovative products and services in over 60 countries worldwide, licensed the rights from Sydnexis to commercialize SYD-101 in the regions of Europe, Middle East, and Africa (EMEA) and will launch SYD-101 under the brand name Ryjunea.

“The EU approval of SYD-101 is a recognition of the compelling safety and efficacy data generated from our landmark STAR study,” said Patrick Johnson, Ph.D., President of Sydnexis. “This validates the potential benefit that SYD-101 can provide to pediatric myopes in Europe and we are excited about our continued interactions with the Food and Drug Administration (FDA) leading up to our October 23 PDUFA date.”

Myopia is the most common eye disease in children, impacting approximately one-third of children and adolescents worldwide. By 2050, global prevalence is projected to increase and affect more than 740 million children and adolescents and 5 billion people in total. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious irreversible sight-threatening co-morbidities later in life.

“As a Pediatric Ophthalmologist with a rapidly growing number of myopia patients around the world, the EU approval of SYD-101 is truly exciting and it provides an important new tool for physicians to combat this global epidemic,” said Dr. Donny Suh, Gavin Herbert Eye Institute, University of California at Irvine. “The benefits of low-dose atropine have long been recognized in the eye care community, but we now finally have an approved and thoroughly vetted treatment option. This marks a new era in our ability to slow the progression of myopia and protect the vision of millions of children worldwide.”

About Sydnexis, Inc.:

Founded in 2014, Sydnexis, Inc. (www.sydnexis.com) is a privately held, pre-commercial stage biopharmaceutical company based in San Diego, California. Sydnexis recently completed its three-year primary endpoint in the pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of pediatric myopia and the risk of associated co-morbidities. The Phase 3 clinical trial is now completing the fourth-year randomized withdrawal for exploratory endpoints and third year results will be announced upon completion of the fourth year of the study. The company is venture-backed by four major investors: Visionary Ventures, RA Capital, Longitude Capital, and Bluestem Capital.

Contacts

For media inquiries, please contact: media@launchlabpartners.com

Next Generation Biotherapeutics Market Research Report 2025: NGBTs Lead the Charge with Advanced Gene and Cell Therapies – Global Industry Size, Share, Trends, Opportunity, and Forecasts 2020-2030F – ResearchAndMarkets.com




Next Generation Biotherapeutics Market Research Report 2025: NGBTs Lead the Charge with Advanced Gene and Cell Therapies – Global Industry Size, Share, Trends, Opportunity, and Forecasts 2020-2030F – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Next Generation Biotherapeutics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F” report has been added to ResearchAndMarkets.com’s offering.

The Next Generation Biotherapeutics Market was valued at USD 5.42 Billion in 2024, and is expected to reach USD 10.75 Billion by 2030, rising at a CAGR of 12.05%

NGBTs signify a transformative leap in biopharmaceutical innovation, utilizing advanced technologies such as gene therapy, cell therapy, RNA interference, and monoclonal antibodies to deliver precise and personalized treatment. These therapies are engineered to target specific disease mechanisms, improving treatment effectiveness while minimizing adverse effects.

Their application spans a wide range of conditions, offering new hope for patients unresponsive to conventional therapies. As the demand for tailored, data-driven healthcare solutions grows, NGBTs are rapidly gaining traction across global healthcare systems. By activating the body’s natural mechanisms and harnessing next-gen molecular strategies, these biotherapeutics are reshaping medical treatment paradigms. With continuous R&D breakthroughs, NGBTs are advancing the possibilities of treating complex and previously untreatable diseases, offering better clinical outcomes and redefining standards in patient care.

Key Market Drivers

Increasing Incidence of Cancer

The escalating global cancer burden is a major factor propelling the demand for Next Generation Biotherapeutics. Cancer rates are expected to rise by 77% by 2050 compared to 2022, highlighting an urgent need for more precise, effective treatment strategies. Traditional treatments like chemotherapy and radiation are often associated with systemic toxicity and limited efficacy.

In contrast, NGBT harnesses advanced genomic profiling to tailor therapies to an individual’s unique genetic profile, targeting cancer at its molecular root. These therapies are designed to overcome resistance mechanisms and minimize damage to healthy tissues, enhancing therapeutic precision and patient quality of life. As the need for more adaptable and less invasive therapies intensifies, NGBTs are positioned as a vital component in the evolving landscape of oncology treatment.

Key Market Trends

Increasing Aging Population

The global demographic shift toward an older population is a major trend fueling demand for NGBTs. By 2050, the population aged 65 and above is expected to grow to 16%, further increasing to 24% by 2100. With age comes a heightened prevalence of chronic and degenerative diseases such as cancer, cardiovascular disorders, and neurodegenerative conditions.

NGBTs provide targeted, innovative therapies tailored to the complex health needs of aging individuals. These biotherapeutics offer a high level of personalization, which is especially critical for elderly patients managing multiple comorbidities. Their potential to reduce hospitalizations and long-term care needs also makes them attractive for healthcare systems aiming to improve outcomes while controlling costs. As aging continues to drive global healthcare demand, NGBTs stand out as a promising solution for personalized, effective disease management in elderly populations.

Key Attributes:

Report Scope:

Key Market Players

• Xencor, Inc.
• Regenxbio & Neurimmune AG
• Takeda Pharmaceutical Company Limited
• Pfizer, Inc.
• AstraZeneca Plc.
• F. Hoffmann-La Roche Ltd.
• Kyowa Kirin Co., Ltd
• Seattle Genetics, Inc
• ImmunoGen, Inc
• Ono Pharmaceuticals Co, Ltd

Next Generation Biotherapeutics Market, By Therapeutic Area:

• Oncology
• Autoimmune/ Inflammatory Diseases

Next Generation Biotherapeutics Market, By Technology:

• Antibody-Drug Conjugates
• Bispecific Antibodies
• Antibody Fragments
• Antibody-like Proteins
• Others

Next Generation Biotherapeutics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

For more information about this report visit https://www.researchandmarkets.com/r/puwv5z

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900